enVVeno Medical Corporation (NVNO) — Financial statements
Income statement, balance sheet, and cash flow for enVVeno Medical Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.53↓3.3% | 0.55↑4.0% | 0.53↑15.9% | 0.45 | |
| Gross Profit | 0.00↑100.0% | -0.53↑3.3% | -0.55↓4.0% | -0.53↓15.9% | -0.45 | |
| Operating Expenses | ||||||
| R&D Expenses | 10↓18.5% | 12↓9.8% | 14↑37.0% | 10↑73.1% | 6 | |
| General & Administrative Expenses | 11 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 11↓1.2% | 11↓0.5% | 11↓23.3% | 14↑35.3% | 11 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 21↓10.3% | 23↓5.6% | 25↑1.2% | 24↑48.5% | 16 | |
| Total Costs & Expenses | 21↓12.3% | 24↓5.6% | 25↑1.2% | 25↑47.6% | 17 | |
| Operating Results | ||||||
| Operating Income | -21↑12.3% | -24↑5.6% | -25↓1.2% | -25↓47.6% | -17 | |
| Depreciation & Amortization | 0.49↓7.4% | 0.53↓3.3% | 0.55↑4.0% | 0.53↑15.9% | 0.45 | |
| EBITDA | -20↑4.1% | -21↑7.3% | -23↑4.9% | -24↓50.2% | -16 | |
| EBIT | -21↑4.2% | -22↑7.2% | -24↑4.7% | -25↓49.3% | -17 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.69↑77.9% | 0.39↑116.1% | 0.18↑11.8% | 0.16↑760.5% | 0.02 | |
| Interest Income | 0.69↑77.9% | 0.39↑116.1% | 0.18↑11.8% | 0.16↑760.5% | 0.02 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -2↓16.6% | -2↓554.8% | -0.26↑27.9% | -0.36 | |
| Other Income / Expenses | 1↓28.9% | 2↑16.6% | 2↑554.8% | 0.26↓27.9% | 0.36 | |
| Income Before Tax | -19↑10.8% | -22↑7.2% | -24↑4.7% | -25↓49.3% | -17 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -19↑10.8% | -22↑7.2% | -24↑4.7% | -25↓49.3% | -17 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -19↑10.8% | -22↑7.2% | -24↑4.7% | -25↓49.3% | -17 | |
| Bottom-Line Net Income | -19↑10.8% | -22↑7.2% | -24↑4.7% | -25↓49.3% | -17 | |
| EPS (Basic) | -33.06↑97.9% | -1,555.75↑33.5% | -2,339.75↑13.2% | -2,695.00↓15.8% | -2,327.50 | |
| EPS (Diluted) | -33.06↑97.9% | -1,555.75↑33.5% | -2,339.75↑13.2% | -2,695.00↓15.8% | -2,327.50 | |
| Weighted Average Shares | 0.59↑4109.2% | 0.01↑39.3% | 0.01↑9.5% | 0.01↑29.4% | 0.01 | |
| Weighted Average Diluted Shares | 0.59↑4109.2% | 0.01↑39.3% | 0.01↑9.5% | 0.01↑29.4% | 0.01 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.